Full Press Release Details
Dupixent® (dupilumab) SmPC Updated with Long-term Data Reinforcing Well-established Safety Profile in Adults with Moderate-to-severe Atopic Dermatitis.
REGN
Dupixent® (dupilumab) SmPC Updated with Long-term Data Reinforcing Well-established Safety Profile in Adults with Moderate-to-severe Atopic Dermatitis
Key Takeaway: Dupixent® (dupilumab) SmPC Updated with Long-term Data Reinforcing Well-established Safety Profile in Adults with Moderate-to-severe Atopic Dermatitis